Avifavir® is the first effective drug for COVID‐19 treatment registered in Russia
Benefits in everything
- both in hospitals and at home
- prevention of hospitalization
- faster recovery
- reduced contagiosity and isolated period
- convenient per os
- decreased burden on hospitals by 3 times
- reduced hospitalization period by 30
- reduced disability period
- support of economy
- prevention of lockdown
Avifavir® status by today
A brief history of the development of Avifavir® in the period 2020-2021 Today Avifavir® is registered in 15 countries of the world. The situation changes daily. Avifavir® has entered the international market and the European Medical Alliance is actively involved in this.
Emergency Use Authorization obtaining via fast-track on 60 patients
The entire presentation
Within the shortest term possible, the ChemRar specialists developed testing platforms and a set of methods for the synthesis of substances and pharmaceutical formulation. On May 29th, 2020, after all the pre-clinical and clinical studies were completed, the medicine was registered and became available to patients.We present to your attention the presentation of Avifavir. If necessary, you can download our files and read them in more detail. We have selected all the answers to your questions.
Description in PDF files
For your convenience, you can view the presentation files in any browser without downloading them. To download files to your device, you need to click the arrow in the right corner, enlarge the file and download from our file store.
Acquisition of Avifavir and cooperation with us
We are interested in working with public and private companies to promote Avifavir worldwide.
Read the description of Avifavir in our introductory presentations.
We are professional corporate consultants specializing in healthcare, pharmaceutical and medical technology companies. We analyze markets, plan new product launches and support investment decisions in the CIS and Central Asia.